{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.0","value":"21.8"},{"groupId":"OG001","spread":"11.7","value":"22.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"110"},{"groupId":"OG001","value":"38"}],"units":"Participants"}],"description":"Apparent oral clearance at steady state, unadjusted for bioavailability (CLss/F) following 15 days of QD dosing","dispersionType":"Standard Deviation","groups":[{"description":"Part 1 and Part 2: Patients received a starting dose of 300 mg QD. Patients received avapritinib in continuous 28 day cycles until discontinuation.","id":"OG000","title":"Part 1 and Part 2: Avapritinib (Formerly BLU-285) 300 mg QD"},{"description":"Part 1 and Part 2: Patients received a starting dose of 400 mg QD. Patients received avapritinib in continuous 28 day cycles until discontinuation.","id":"OG001","title":"Part 1 and Part 2: Avapritinib (Formerly BLU-285) 400 mg QD"}],"paramType":"MEAN","populationDescription":"Patients enrolled in Part 1 and Part 2 with a starting dose of 300 or 400 mg QD and available samples for PK","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 15","title":"Apparent Oral Clearance at Steady State, Unadjusted for Bioavailability (CLss/F)","type":"SECONDARY","unitOfMeasure":"L/h"}